EA202190306A1 - COMBINATIONS AND METHODS INCLUDING CAPSID ASSEMBLY INHIBITOR - Google Patents
COMBINATIONS AND METHODS INCLUDING CAPSID ASSEMBLY INHIBITORInfo
- Publication number
- EA202190306A1 EA202190306A1 EA202190306A EA202190306A EA202190306A1 EA 202190306 A1 EA202190306 A1 EA 202190306A1 EA 202190306 A EA202190306 A EA 202190306A EA 202190306 A EA202190306 A EA 202190306A EA 202190306 A1 EA202190306 A1 EA 202190306A1
- Authority
- EA
- Eurasian Patent Office
- Prior art keywords
- combinations
- capsid assembly
- methods including
- assembly inhibitor
- including capsid
- Prior art date
Links
- 210000000234 capsid Anatomy 0.000 title abstract 2
- 239000003112 inhibitor Substances 0.000 title abstract 2
- 208000036142 Viral infection Diseases 0.000 abstract 1
- 208000002672 hepatitis B Diseases 0.000 abstract 1
- 239000000203 mixture Substances 0.000 abstract 1
- 230000009385 viral infection Effects 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/02—Halogenated hydrocarbons
- A61K31/025—Halogenated hydrocarbons carbocyclic
- A61K31/03—Halogenated hydrocarbons carbocyclic aromatic
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
- A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7068—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid
- A61K31/7072—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines having oxo groups directly attached to the pyrimidine ring, e.g. cytidine, cytidylic acid having two oxo groups directly attached to the pyrimidine ring, e.g. uridine, uridylic acid, thymidine, zidovudine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- C12N7/04—Inactivation or attenuation; Producing viral sub-units
- C12N7/06—Inactivation or attenuation by chemical treatment
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Virology (AREA)
- Oncology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Изобретение относится к композициям ингибиторов сборки капсида и способам их применения в лечении вирусной инфекции гепатита B.The invention relates to compositions of capsid assembly inhibitors and methods of their use in the treatment of hepatitis B viral infection.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201662421035P | 2016-11-11 | 2016-11-11 |
Publications (1)
Publication Number | Publication Date |
---|---|
EA202190306A1 true EA202190306A1 (en) | 2021-08-17 |
Family
ID=65950021
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201892348A EA037576B1 (en) | 2016-11-11 | 2017-04-14 | Combinations and methods comprising a capsid assembly inhibitor |
EA202190306A EA202190306A1 (en) | 2016-11-11 | 2017-04-14 | COMBINATIONS AND METHODS INCLUDING CAPSID ASSEMBLY INHIBITOR |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
EA201892348A EA037576B1 (en) | 2016-11-11 | 2017-04-14 | Combinations and methods comprising a capsid assembly inhibitor |
Country Status (1)
Country | Link |
---|---|
EA (2) | EA037576B1 (en) |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AR090044A1 (en) * | 2011-12-21 | 2014-10-15 | Novira Therapeutics Inc | ANTIVIRAL AGENTS FOR HEPATITIS B |
MX2015008471A (en) * | 2012-12-27 | 2016-10-26 | Univ Drexel | Novel antiviral agents against hbv infection. |
JO3603B1 (en) * | 2013-05-17 | 2020-07-05 | Janssen Sciences Ireland Uc | Sulfamoyl pyrolamide derivatives and their use as medicines to treat hepatitis B |
US9169212B2 (en) * | 2014-01-16 | 2015-10-27 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
US9181288B2 (en) * | 2014-01-16 | 2015-11-10 | Novira Therapeutics, Inc. | Azepane derivatives and methods of treating hepatitis B infections |
PL3102572T3 (en) * | 2014-02-06 | 2019-04-30 | Janssen Sciences Ireland Uc | Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis b |
US9400280B2 (en) * | 2014-03-27 | 2016-07-26 | Novira Therapeutics, Inc. | Piperidine derivatives and methods of treating hepatitis B infections |
-
2017
- 2017-04-14 EA EA201892348A patent/EA037576B1/en not_active IP Right Cessation
- 2017-04-14 EA EA202190306A patent/EA202190306A1/en unknown
Also Published As
Publication number | Publication date |
---|---|
EA037576B1 (en) | 2021-04-15 |
EA201892348A1 (en) | 2019-03-29 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EA201691726A1 (en) | NEW 6-CONDENSED HETEROARYDYDYDROPYRIMIDIDES FOR THE TREATMENT AND PREVENTION OF HEPATITIS B VIRUS INFECTION | |
MX2020011808A (en) | Combinations and methods comprising a capsid assembly inhibitor. | |
EA201791460A1 (en) | N4-HYDROXYCYTIDINE AND RELATED DERIVATIVES AND OPTIONS FOR ANTI-VIRUS APPLICATION | |
MX377531B (en) | COMBINATION THERAPY OF AN HBV CAPSID ASSEMBLY INHIBITOR AND AN INTERFERON. | |
EA201691261A1 (en) | NEW DIHYDROCHINOLYSINES FOR THE TREATMENT AND PREVENTION OF INFECTION CAUSED BY THE HEPATITIS B VIRUS | |
EA201792069A1 (en) | DERIVATIVES OF AZOKANES AND AZONAS AND METHODS OF TREATING INFECTIONS OF HEPATITIS B | |
EA201691440A1 (en) | AZEPAN DERIVATIVES AND METHODS OF TREATING HEPATITIS B INFECTIONS | |
EA201790630A1 (en) | METHODS OF OBTAINING RIBOSIDS | |
JOP20180008A1 (en) | Compounds for the treatment of hepatitis b virus infection | |
EA201790413A1 (en) | ANTIBODIES AGAINST TIGIT | |
JOP20200092A1 (en) | HEPATITIS B VIRUS (HBV) iRNA COMPOSITIONS AND METHODS OF USE THEREOF | |
EA201790273A1 (en) | FLAGELLIN COMPOSITIONS AND THEIR APPLICATION | |
EA201692358A1 (en) | IZOINDOLIN DERIVATIVES FOR USE IN THE TREATMENT OF VIRAL INFECTION | |
EA201890810A1 (en) | COMPOUNDS EFFECTIVE FOR THE TREATMENT OF HEPATOTOXICITY AND LIVER STEATOSIS AND THEIR APPLICATION | |
EA202091849A1 (en) | THIAZOLIDE COMPOUNDS FOR TREATMENT OF VIRAL INFECTIONS | |
EA202090693A1 (en) | NEW MEK INHIBITOR FOR TREATMENT OF VIRAL AND BACTERIAL INFECTIONS | |
EA201790517A1 (en) | METHODS AND COMPOSITIONS FOR INDUCING PROTECTIVE IMMUNITY AGAINST PHILOVIRUS INFECTION | |
EA201692034A1 (en) | NEW MACROCYCLIC COMPOUNDS | |
EP3833672C0 (en) | TRICYCLIC INHIBITORS OF HEPATITIS C VIRUS | |
EA201690594A1 (en) | COMPOSITION FOR THE TREATMENT OF HIV INFECTION ON THE BASIS OF ATAZANAVIR AND COBICISTAT | |
EA201890818A1 (en) | COMBINED TREATMENT FOR HCV TREATMENT | |
JOP20190214A1 (en) | subbstituted Dihydroindene-4-Carboxamides and Analogs Thereof, and Methods Using Same | |
EA201790771A1 (en) | PHARMACEUTICAL COMPOSITIONS OF LONG-TERM ACTION FOR THE TREATMENT OF HEPATITIS C | |
EA201790776A1 (en) | COMBINED COMPOSITIONS OF LONG-TERM ACTIONS AND METHODS OF TREATING HEPATITIS C | |
TR201722950A2 (en) | New pharmaceutical compositions in the treatment of COPD. |